Positive results from ocrelizumab phase II RRMS study
Positive results from ocrelizumab phase II RRMS study
Roche and Biogen Idec announced 24-week results from a phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of the disease.
Ocrelizumab demonstrated a significant reduction in disease activity as measured by brain lesions and relapse rate. Patients with RRMS suffer from relapses and disabling symptoms caused by nerve damage which can significantly affect their quality of life.
“These efficacy results are amongst the most remarkable seen in a phase II RRMS study, and show that ocrelizumab may have the potential to offer benefits to patients with this disease”... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1572 Views
-
Last post by NHE
-
- 0 Replies
- 1019 Views
-
Last post by NHE
-
- 0 Replies
- 10810 Views
-
Last post by NHE
-
- 8 Replies
- 7334 Views
-
Last post by Algis
-
- 0 Replies
- 641 Views
-
Last post by DIM
-
- 0 Replies
- 2313 Views
-
Last post by NHE
-
- 0 Replies
- 1189 Views
-
Last post by frodo
-
- 1 Replies
- 2880 Views
-
Last post by Tif
-
- 2 Replies
- 4098 Views
-
Last post by DIM